nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—Diarrhoea—Sunitinib—pancreatic cancer	0.000687	0.00105	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000684	0.00104	CcSEcCtD
Zuclopenthixol—Ataxia—Doxorubicin—pancreatic cancer	0.000683	0.00104	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Irinotecan—pancreatic cancer	0.000682	0.00104	CcSEcCtD
Zuclopenthixol—Pain—Fluorouracil—pancreatic cancer	0.000678	0.00103	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000677	0.00103	CcSEcCtD
Zuclopenthixol—Eosinophilia—Epirubicin—pancreatic cancer	0.000672	0.00102	CcSEcCtD
Zuclopenthixol—Liver function test abnormal—Doxorubicin—pancreatic cancer	0.000671	0.00102	CcSEcCtD
Zuclopenthixol—Dizziness—Sunitinib—pancreatic cancer	0.000664	0.00101	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000664	0.00101	CcSEcCtD
Zuclopenthixol—Breast disorder—Doxorubicin—pancreatic cancer	0.000656	0.000999	CcSEcCtD
Zuclopenthixol—Body temperature increased—Irinotecan—pancreatic cancer	0.000654	0.000996	CcSEcCtD
Zuclopenthixol—Abdominal pain—Irinotecan—pancreatic cancer	0.000654	0.000996	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000653	0.000994	CcSEcCtD
Zuclopenthixol—Nasopharyngitis—Doxorubicin—pancreatic cancer	0.00065	0.000989	CcSEcCtD
Zuclopenthixol—Pancytopenia—Epirubicin—pancreatic cancer	0.000644	0.000981	CcSEcCtD
Zuclopenthixol—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.000641	0.000975	CcSEcCtD
Zuclopenthixol—Vomiting—Sunitinib—pancreatic cancer	0.000639	0.000972	CcSEcCtD
Zuclopenthixol—Body temperature increased—Gemcitabine—pancreatic cancer	0.000637	0.00097	CcSEcCtD
Zuclopenthixol—Neutropenia—Epirubicin—pancreatic cancer	0.000635	0.000966	CcSEcCtD
Zuclopenthixol—Dysuria—Epirubicin—pancreatic cancer	0.000635	0.000966	CcSEcCtD
Zuclopenthixol—Rash—Sunitinib—pancreatic cancer	0.000633	0.000964	CcSEcCtD
Zuclopenthixol—Dermatitis—Sunitinib—pancreatic cancer	0.000633	0.000963	CcSEcCtD
Zuclopenthixol—Headache—Sunitinib—pancreatic cancer	0.000629	0.000958	CcSEcCtD
Zuclopenthixol—Syncope—Docetaxel—pancreatic cancer	0.000629	0.000957	CcSEcCtD
Zuclopenthixol—Leukopenia—Docetaxel—pancreatic cancer	0.000627	0.000955	CcSEcCtD
Zuclopenthixol—Body temperature increased—Fluorouracil—pancreatic cancer	0.000627	0.000954	CcSEcCtD
Zuclopenthixol—Eosinophilia—Doxorubicin—pancreatic cancer	0.000622	0.000946	CcSEcCtD
Zuclopenthixol—Palpitations—Docetaxel—pancreatic cancer	0.000619	0.000943	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.000619	0.000943	CcSEcCtD
Zuclopenthixol—Weight increased—Epirubicin—pancreatic cancer	0.000618	0.00094	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Docetaxel—pancreatic cancer	0.000616	0.000938	CcSEcCtD
Zuclopenthixol—Weight decreased—Epirubicin—pancreatic cancer	0.000614	0.000934	CcSEcCtD
Zuclopenthixol—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000612	0.000932	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Irinotecan—pancreatic cancer	0.00061	0.000928	CcSEcCtD
Zuclopenthixol—Convulsion—Docetaxel—pancreatic cancer	0.000607	0.000924	CcSEcCtD
Zuclopenthixol—Hypertension—Docetaxel—pancreatic cancer	0.000605	0.000921	CcSEcCtD
Zuclopenthixol—Drowsiness—Epirubicin—pancreatic cancer	0.000605	0.000921	CcSEcCtD
Zuclopenthixol—Myalgia—Docetaxel—pancreatic cancer	0.000597	0.000908	CcSEcCtD
Zuclopenthixol—Nausea—Sunitinib—pancreatic cancer	0.000597	0.000908	CcSEcCtD
Zuclopenthixol—Pancytopenia—Doxorubicin—pancreatic cancer	0.000596	0.000908	CcSEcCtD
Zuclopenthixol—Asthenia—Irinotecan—pancreatic cancer	0.000594	0.000904	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000593	0.000902	CcSEcCtD
Zuclopenthixol—Jaundice—Epirubicin—pancreatic cancer	0.00059	0.000898	CcSEcCtD
Zuclopenthixol—Neutropenia—Doxorubicin—pancreatic cancer	0.000587	0.000894	CcSEcCtD
Zuclopenthixol—Dysuria—Doxorubicin—pancreatic cancer	0.000587	0.000894	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000584	0.000889	CcSEcCtD
Zuclopenthixol—Dry mouth—Docetaxel—pancreatic cancer	0.000584	0.000888	CcSEcCtD
Zuclopenthixol—Sweating—Epirubicin—pancreatic cancer	0.00058	0.000883	CcSEcCtD
Zuclopenthixol—Asthenia—Gemcitabine—pancreatic cancer	0.000578	0.00088	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000573	0.000872	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000572	0.000871	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000572	0.000871	CcSEcCtD
Zuclopenthixol—Weight increased—Doxorubicin—pancreatic cancer	0.000571	0.00087	CcSEcCtD
Zuclopenthixol—Pruritus—Gemcitabine—pancreatic cancer	0.00057	0.000868	CcSEcCtD
Zuclopenthixol—Weight decreased—Doxorubicin—pancreatic cancer	0.000568	0.000865	CcSEcCtD
Zuclopenthixol—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000566	0.000862	CcSEcCtD
Zuclopenthixol—Diarrhoea—Irinotecan—pancreatic cancer	0.000566	0.000862	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Epirubicin—pancreatic cancer	0.000565	0.000859	CcSEcCtD
Zuclopenthixol—Shock—Docetaxel—pancreatic cancer	0.000563	0.000857	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Docetaxel—pancreatic cancer	0.000561	0.000854	CcSEcCtD
Zuclopenthixol—Pruritus—Fluorouracil—pancreatic cancer	0.000561	0.000854	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Docetaxel—pancreatic cancer	0.00056	0.000853	CcSEcCtD
Zuclopenthixol—Drowsiness—Doxorubicin—pancreatic cancer	0.00056	0.000852	CcSEcCtD
Zuclopenthixol—Tachycardia—Docetaxel—pancreatic cancer	0.000558	0.00085	CcSEcCtD
Zuclopenthixol—Skin disorder—Docetaxel—pancreatic cancer	0.000556	0.000846	CcSEcCtD
Zuclopenthixol—Diarrhoea—Gemcitabine—pancreatic cancer	0.000552	0.00084	CcSEcCtD
Zuclopenthixol—Dizziness—Irinotecan—pancreatic cancer	0.000547	0.000833	CcSEcCtD
Zuclopenthixol—Jaundice—Doxorubicin—pancreatic cancer	0.000546	0.000831	CcSEcCtD
Zuclopenthixol—Anorexia—Docetaxel—pancreatic cancer	0.000545	0.00083	CcSEcCtD
Zuclopenthixol—Diarrhoea—Fluorouracil—pancreatic cancer	0.000542	0.000825	CcSEcCtD
Zuclopenthixol—Sweating—Doxorubicin—pancreatic cancer	0.000537	0.000817	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000536	0.000816	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Epirubicin—pancreatic cancer	0.000535	0.000814	CcSEcCtD
Zuclopenthixol—Hypotension—Docetaxel—pancreatic cancer	0.000535	0.000814	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000534	0.000812	CcSEcCtD
Zuclopenthixol—Urethral disorder—Epirubicin—pancreatic cancer	0.000532	0.00081	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000529	0.000806	CcSEcCtD
Zuclopenthixol—Vomiting—Irinotecan—pancreatic cancer	0.000526	0.000801	CcSEcCtD
Zuclopenthixol—Dizziness—Fluorouracil—pancreatic cancer	0.000524	0.000798	CcSEcCtD
Zuclopenthixol—Visual impairment—Epirubicin—pancreatic cancer	0.000523	0.000797	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Doxorubicin—pancreatic cancer	0.000522	0.000795	CcSEcCtD
Zuclopenthixol—Rash—Irinotecan—pancreatic cancer	0.000522	0.000794	CcSEcCtD
Zuclopenthixol—Dermatitis—Irinotecan—pancreatic cancer	0.000521	0.000793	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000521	0.000793	CcSEcCtD
Zuclopenthixol—Headache—Irinotecan—pancreatic cancer	0.000518	0.000789	CcSEcCtD
Zuclopenthixol—Insomnia—Docetaxel—pancreatic cancer	0.000517	0.000788	CcSEcCtD
Zuclopenthixol—Paraesthesia—Docetaxel—pancreatic cancer	0.000514	0.000782	CcSEcCtD
Zuclopenthixol—Vomiting—Gemcitabine—pancreatic cancer	0.000513	0.00078	CcSEcCtD
Zuclopenthixol—Dyspnoea—Docetaxel—pancreatic cancer	0.00051	0.000776	CcSEcCtD
Zuclopenthixol—Somnolence—Docetaxel—pancreatic cancer	0.000509	0.000774	CcSEcCtD
Zuclopenthixol—Rash—Gemcitabine—pancreatic cancer	0.000508	0.000774	CcSEcCtD
Zuclopenthixol—Dermatitis—Gemcitabine—pancreatic cancer	0.000508	0.000773	CcSEcCtD
Zuclopenthixol—Eye disorder—Epirubicin—pancreatic cancer	0.000508	0.000773	CcSEcCtD
Zuclopenthixol—Tinnitus—Epirubicin—pancreatic cancer	0.000506	0.000771	CcSEcCtD
Zuclopenthixol—Headache—Gemcitabine—pancreatic cancer	0.000505	0.000769	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Epirubicin—pancreatic cancer	0.000504	0.000767	CcSEcCtD
Zuclopenthixol—Vomiting—Fluorouracil—pancreatic cancer	0.000504	0.000767	CcSEcCtD
Zuclopenthixol—Dyspepsia—Docetaxel—pancreatic cancer	0.000504	0.000766	CcSEcCtD
Zuclopenthixol—Rash—Fluorouracil—pancreatic cancer	0.0005	0.000761	CcSEcCtD
Zuclopenthixol—Dermatitis—Fluorouracil—pancreatic cancer	0.000499	0.00076	CcSEcCtD
Zuclopenthixol—Decreased appetite—Docetaxel—pancreatic cancer	0.000497	0.000757	CcSEcCtD
Zuclopenthixol—Headache—Fluorouracil—pancreatic cancer	0.000497	0.000756	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000496	0.000755	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000495	0.000753	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000494	0.000752	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000494	0.000752	CcSEcCtD
Zuclopenthixol—Fatigue—Docetaxel—pancreatic cancer	0.000493	0.000751	CcSEcCtD
Zuclopenthixol—Angiopathy—Epirubicin—pancreatic cancer	0.000493	0.00075	CcSEcCtD
Zuclopenthixol—Urethral disorder—Doxorubicin—pancreatic cancer	0.000493	0.00075	CcSEcCtD
Zuclopenthixol—Nausea—Irinotecan—pancreatic cancer	0.000492	0.000748	CcSEcCtD
Zuclopenthixol—Immune system disorder—Epirubicin—pancreatic cancer	0.000491	0.000747	CcSEcCtD
Zuclopenthixol—Pain—Docetaxel—pancreatic cancer	0.000489	0.000745	CcSEcCtD
Zuclopenthixol—Constipation—Docetaxel—pancreatic cancer	0.000489	0.000745	CcSEcCtD
Zuclopenthixol—Arrhythmia—Epirubicin—pancreatic cancer	0.000485	0.000738	CcSEcCtD
Zuclopenthixol—Visual impairment—Doxorubicin—pancreatic cancer	0.000484	0.000737	CcSEcCtD
Zuclopenthixol—Nausea—Gemcitabine—pancreatic cancer	0.000479	0.000729	CcSEcCtD
Zuclopenthixol—Mental disorder—Epirubicin—pancreatic cancer	0.000476	0.000724	CcSEcCtD
Zuclopenthixol—Malnutrition—Epirubicin—pancreatic cancer	0.000473	0.00072	CcSEcCtD
Zuclopenthixol—Erythema—Epirubicin—pancreatic cancer	0.000473	0.00072	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Docetaxel—pancreatic cancer	0.000471	0.000718	CcSEcCtD
Zuclopenthixol—Nausea—Fluorouracil—pancreatic cancer	0.000471	0.000717	CcSEcCtD
Zuclopenthixol—Eye disorder—Doxorubicin—pancreatic cancer	0.00047	0.000715	CcSEcCtD
Zuclopenthixol—Tinnitus—Doxorubicin—pancreatic cancer	0.000469	0.000713	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000468	0.000712	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000466	0.00071	CcSEcCtD
Zuclopenthixol—Flatulence—Epirubicin—pancreatic cancer	0.000466	0.000709	CcSEcCtD
Zuclopenthixol—Tension—Epirubicin—pancreatic cancer	0.000464	0.000706	CcSEcCtD
Zuclopenthixol—Nervousness—Epirubicin—pancreatic cancer	0.000459	0.000699	CcSEcCtD
Zuclopenthixol—Angiopathy—Doxorubicin—pancreatic cancer	0.000456	0.000694	CcSEcCtD
Zuclopenthixol—Immune system disorder—Doxorubicin—pancreatic cancer	0.000454	0.000691	CcSEcCtD
Zuclopenthixol—Abdominal pain—Docetaxel—pancreatic cancer	0.000452	0.000688	CcSEcCtD
Zuclopenthixol—Body temperature increased—Docetaxel—pancreatic cancer	0.000452	0.000688	CcSEcCtD
Zuclopenthixol—Arrhythmia—Doxorubicin—pancreatic cancer	0.000449	0.000683	CcSEcCtD
Zuclopenthixol—Vision blurred—Epirubicin—pancreatic cancer	0.000446	0.000678	CcSEcCtD
Zuclopenthixol—Mental disorder—Doxorubicin—pancreatic cancer	0.00044	0.00067	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000439	0.000668	CcSEcCtD
Zuclopenthixol—Erythema—Doxorubicin—pancreatic cancer	0.000437	0.000666	CcSEcCtD
Zuclopenthixol—Malnutrition—Doxorubicin—pancreatic cancer	0.000437	0.000666	CcSEcCtD
Zuclopenthixol—Agitation—Epirubicin—pancreatic cancer	0.000435	0.000661	CcSEcCtD
Zuclopenthixol—Flatulence—Doxorubicin—pancreatic cancer	0.000431	0.000656	CcSEcCtD
Zuclopenthixol—Tension—Doxorubicin—pancreatic cancer	0.000429	0.000653	CcSEcCtD
Zuclopenthixol—Malaise—Epirubicin—pancreatic cancer	0.000426	0.000649	CcSEcCtD
Zuclopenthixol—Nervousness—Doxorubicin—pancreatic cancer	0.000425	0.000647	CcSEcCtD
Zuclopenthixol—Vertigo—Epirubicin—pancreatic cancer	0.000425	0.000647	CcSEcCtD
Zuclopenthixol—Syncope—Epirubicin—pancreatic cancer	0.000424	0.000645	CcSEcCtD
Zuclopenthixol—Leukopenia—Epirubicin—pancreatic cancer	0.000423	0.000644	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Docetaxel—pancreatic cancer	0.000422	0.000642	CcSEcCtD
Zuclopenthixol—Palpitations—Epirubicin—pancreatic cancer	0.000418	0.000636	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Epirubicin—pancreatic cancer	0.000416	0.000632	CcSEcCtD
Zuclopenthixol—Vision blurred—Doxorubicin—pancreatic cancer	0.000412	0.000628	CcSEcCtD
Zuclopenthixol—Asthenia—Docetaxel—pancreatic cancer	0.00041	0.000625	CcSEcCtD
Zuclopenthixol—Convulsion—Epirubicin—pancreatic cancer	0.00041	0.000623	CcSEcCtD
Zuclopenthixol—Hypertension—Epirubicin—pancreatic cancer	0.000408	0.000621	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000406	0.000618	CcSEcCtD
Zuclopenthixol—Pruritus—Docetaxel—pancreatic cancer	0.000405	0.000616	CcSEcCtD
Zuclopenthixol—Myalgia—Epirubicin—pancreatic cancer	0.000403	0.000613	CcSEcCtD
Zuclopenthixol—Agitation—Doxorubicin—pancreatic cancer	0.000402	0.000612	CcSEcCtD
Zuclopenthixol—Anxiety—Epirubicin—pancreatic cancer	0.000401	0.000611	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.0004	0.000608	CcSEcCtD
Zuclopenthixol—Discomfort—Epirubicin—pancreatic cancer	0.000398	0.000605	CcSEcCtD
Zuclopenthixol—Malaise—Doxorubicin—pancreatic cancer	0.000395	0.0006	CcSEcCtD
Zuclopenthixol—Dry mouth—Epirubicin—pancreatic cancer	0.000394	0.000599	CcSEcCtD
Zuclopenthixol—Vertigo—Doxorubicin—pancreatic cancer	0.000393	0.000598	CcSEcCtD
Zuclopenthixol—Syncope—Doxorubicin—pancreatic cancer	0.000392	0.000597	CcSEcCtD
Zuclopenthixol—Leukopenia—Doxorubicin—pancreatic cancer	0.000392	0.000596	CcSEcCtD
Zuclopenthixol—Diarrhoea—Docetaxel—pancreatic cancer	0.000391	0.000596	CcSEcCtD
Zuclopenthixol—Palpitations—Doxorubicin—pancreatic cancer	0.000387	0.000588	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000386	0.000587	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000385	0.000585	CcSEcCtD
Zuclopenthixol—Shock—Epirubicin—pancreatic cancer	0.00038	0.000578	CcSEcCtD
Zuclopenthixol—Convulsion—Doxorubicin—pancreatic cancer	0.000379	0.000577	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Epirubicin—pancreatic cancer	0.000378	0.000576	CcSEcCtD
Zuclopenthixol—Dizziness—Docetaxel—pancreatic cancer	0.000378	0.000576	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000378	0.000575	CcSEcCtD
Zuclopenthixol—Hypertension—Doxorubicin—pancreatic cancer	0.000378	0.000575	CcSEcCtD
Zuclopenthixol—Tachycardia—Epirubicin—pancreatic cancer	0.000377	0.000573	CcSEcCtD
Zuclopenthixol—Skin disorder—Epirubicin—pancreatic cancer	0.000375	0.00057	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000373	0.000568	CcSEcCtD
Zuclopenthixol—Myalgia—Doxorubicin—pancreatic cancer	0.000372	0.000567	CcSEcCtD
Zuclopenthixol—Anxiety—Doxorubicin—pancreatic cancer	0.000371	0.000565	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.00037	0.000563	CcSEcCtD
Zuclopenthixol—Discomfort—Doxorubicin—pancreatic cancer	0.000368	0.00056	CcSEcCtD
Zuclopenthixol—Anorexia—Epirubicin—pancreatic cancer	0.000368	0.00056	CcSEcCtD
Zuclopenthixol—Dry mouth—Doxorubicin—pancreatic cancer	0.000364	0.000554	CcSEcCtD
Zuclopenthixol—Vomiting—Docetaxel—pancreatic cancer	0.000364	0.000554	CcSEcCtD
Zuclopenthixol—Rash—Docetaxel—pancreatic cancer	0.000361	0.000549	CcSEcCtD
Zuclopenthixol—Hypotension—Epirubicin—pancreatic cancer	0.000361	0.000549	CcSEcCtD
Zuclopenthixol—Dermatitis—Docetaxel—pancreatic cancer	0.00036	0.000548	CcSEcCtD
Zuclopenthixol—Headache—Docetaxel—pancreatic cancer	0.000358	0.000545	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000357	0.000543	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000352	0.000535	CcSEcCtD
Zuclopenthixol—Shock—Doxorubicin—pancreatic cancer	0.000351	0.000535	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Doxorubicin—pancreatic cancer	0.00035	0.000533	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.00035	0.000532	CcSEcCtD
Zuclopenthixol—Insomnia—Epirubicin—pancreatic cancer	0.000349	0.000531	CcSEcCtD
Zuclopenthixol—Tachycardia—Doxorubicin—pancreatic cancer	0.000348	0.00053	CcSEcCtD
Zuclopenthixol—Skin disorder—Doxorubicin—pancreatic cancer	0.000347	0.000528	CcSEcCtD
Zuclopenthixol—Paraesthesia—Epirubicin—pancreatic cancer	0.000347	0.000527	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000345	0.000525	CcSEcCtD
Zuclopenthixol—Dyspnoea—Epirubicin—pancreatic cancer	0.000344	0.000524	CcSEcCtD
Zuclopenthixol—Somnolence—Epirubicin—pancreatic cancer	0.000343	0.000522	CcSEcCtD
Zuclopenthixol—Anorexia—Doxorubicin—pancreatic cancer	0.00034	0.000518	CcSEcCtD
Zuclopenthixol—Nausea—Docetaxel—pancreatic cancer	0.00034	0.000517	CcSEcCtD
Zuclopenthixol—Dyspepsia—Epirubicin—pancreatic cancer	0.00034	0.000517	CcSEcCtD
Zuclopenthixol—Decreased appetite—Epirubicin—pancreatic cancer	0.000335	0.000511	CcSEcCtD
Zuclopenthixol—Hypotension—Doxorubicin—pancreatic cancer	0.000334	0.000508	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000333	0.000507	CcSEcCtD
Zuclopenthixol—Fatigue—Epirubicin—pancreatic cancer	0.000333	0.000506	CcSEcCtD
Zuclopenthixol—Pain—Epirubicin—pancreatic cancer	0.00033	0.000502	CcSEcCtD
Zuclopenthixol—Constipation—Epirubicin—pancreatic cancer	0.00033	0.000502	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000325	0.000495	CcSEcCtD
Zuclopenthixol—Insomnia—Doxorubicin—pancreatic cancer	0.000323	0.000491	CcSEcCtD
Zuclopenthixol—Paraesthesia—Doxorubicin—pancreatic cancer	0.000321	0.000488	CcSEcCtD
Zuclopenthixol—Dyspnoea—Doxorubicin—pancreatic cancer	0.000318	0.000484	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Epirubicin—pancreatic cancer	0.000318	0.000484	CcSEcCtD
Zuclopenthixol—Somnolence—Doxorubicin—pancreatic cancer	0.000317	0.000483	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000316	0.00048	CcSEcCtD
Zuclopenthixol—Dyspepsia—Doxorubicin—pancreatic cancer	0.000314	0.000478	CcSEcCtD
Zuclopenthixol—Decreased appetite—Doxorubicin—pancreatic cancer	0.00031	0.000472	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000308	0.000469	CcSEcCtD
Zuclopenthixol—Fatigue—Doxorubicin—pancreatic cancer	0.000308	0.000469	CcSEcCtD
Zuclopenthixol—Pain—Doxorubicin—pancreatic cancer	0.000305	0.000465	CcSEcCtD
Zuclopenthixol—Constipation—Doxorubicin—pancreatic cancer	0.000305	0.000465	CcSEcCtD
Zuclopenthixol—Abdominal pain—Epirubicin—pancreatic cancer	0.000305	0.000464	CcSEcCtD
Zuclopenthixol—Body temperature increased—Epirubicin—pancreatic cancer	0.000305	0.000464	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000294	0.000448	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000292	0.000444	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Epirubicin—pancreatic cancer	0.000284	0.000433	CcSEcCtD
Zuclopenthixol—Abdominal pain—Doxorubicin—pancreatic cancer	0.000282	0.00043	CcSEcCtD
Zuclopenthixol—Body temperature increased—Doxorubicin—pancreatic cancer	0.000282	0.00043	CcSEcCtD
Zuclopenthixol—Asthenia—Epirubicin—pancreatic cancer	0.000277	0.000421	CcSEcCtD
Zuclopenthixol—Pruritus—Epirubicin—pancreatic cancer	0.000273	0.000416	CcSEcCtD
Zuclopenthixol—Diarrhoea—Epirubicin—pancreatic cancer	0.000264	0.000402	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000263	0.0004	CcSEcCtD
Zuclopenthixol—Asthenia—Doxorubicin—pancreatic cancer	0.000256	0.00039	CcSEcCtD
Zuclopenthixol—Dizziness—Epirubicin—pancreatic cancer	0.000255	0.000388	CcSEcCtD
Zuclopenthixol—Pruritus—Doxorubicin—pancreatic cancer	0.000253	0.000384	CcSEcCtD
Zuclopenthixol—Vomiting—Epirubicin—pancreatic cancer	0.000245	0.000373	CcSEcCtD
Zuclopenthixol—Diarrhoea—Doxorubicin—pancreatic cancer	0.000244	0.000372	CcSEcCtD
Zuclopenthixol—Rash—Epirubicin—pancreatic cancer	0.000243	0.00037	CcSEcCtD
Zuclopenthixol—Dermatitis—Epirubicin—pancreatic cancer	0.000243	0.00037	CcSEcCtD
Zuclopenthixol—Headache—Epirubicin—pancreatic cancer	0.000242	0.000368	CcSEcCtD
Zuclopenthixol—Dizziness—Doxorubicin—pancreatic cancer	0.000236	0.000359	CcSEcCtD
Zuclopenthixol—Nausea—Epirubicin—pancreatic cancer	0.000229	0.000349	CcSEcCtD
Zuclopenthixol—Vomiting—Doxorubicin—pancreatic cancer	0.000227	0.000346	CcSEcCtD
Zuclopenthixol—Rash—Doxorubicin—pancreatic cancer	0.000225	0.000343	CcSEcCtD
Zuclopenthixol—Dermatitis—Doxorubicin—pancreatic cancer	0.000225	0.000342	CcSEcCtD
Zuclopenthixol—Headache—Doxorubicin—pancreatic cancer	0.000224	0.00034	CcSEcCtD
Zuclopenthixol—Nausea—Doxorubicin—pancreatic cancer	0.000212	0.000323	CcSEcCtD
Zuclopenthixol—HTR2A—Signaling Pathways—HIF1A—pancreatic cancer	3.99e-05	0.000116	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—CXCL8—pancreatic cancer	3.99e-05	0.000116	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—HIF1A—pancreatic cancer	3.98e-05	0.000116	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TSC2—pancreatic cancer	3.98e-05	0.000116	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TSC2—pancreatic cancer	3.97e-05	0.000116	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—APOE—pancreatic cancer	3.96e-05	0.000115	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—STK11—pancreatic cancer	3.95e-05	0.000115	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—MYC—pancreatic cancer	3.92e-05	0.000114	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—AKT1—pancreatic cancer	3.91e-05	0.000114	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—TGFB1—pancreatic cancer	3.91e-05	0.000114	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—HIF1A—pancreatic cancer	3.91e-05	0.000114	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TSC2—pancreatic cancer	3.9e-05	0.000114	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—APOE—pancreatic cancer	3.9e-05	0.000114	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—APOE—pancreatic cancer	3.89e-05	0.000113	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—KDR—pancreatic cancer	3.88e-05	0.000113	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CASP3—pancreatic cancer	3.88e-05	0.000113	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—EGFR—pancreatic cancer	3.83e-05	0.000112	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PIK3CG—pancreatic cancer	3.83e-05	0.000112	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—KDR—pancreatic cancer	3.82e-05	0.000111	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—APOE—pancreatic cancer	3.82e-05	0.000111	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—KDR—pancreatic cancer	3.81e-05	0.000111	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TERT—pancreatic cancer	3.8e-05	0.000111	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CCND1—pancreatic cancer	3.77e-05	0.00011	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—PIK3CA—pancreatic cancer	3.74e-05	0.000109	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—KDR—pancreatic cancer	3.74e-05	0.000109	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CTNNB1—pancreatic cancer	3.74e-05	0.000109	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PPARG—pancreatic cancer	3.69e-05	0.000108	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NFKBIA—pancreatic cancer	3.69e-05	0.000108	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MMP9—pancreatic cancer	3.66e-05	0.000107	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NOTCH1—pancreatic cancer	3.65e-05	0.000107	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—PTEN—pancreatic cancer	3.64e-05	0.000106	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—HIF1A—pancreatic cancer	3.63e-05	0.000106	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NFKBIA—pancreatic cancer	3.63e-05	0.000106	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PIK3CB—pancreatic cancer	3.63e-05	0.000106	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NFKBIA—pancreatic cancer	3.62e-05	0.000106	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TSC2—pancreatic cancer	3.62e-05	0.000106	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—KRAS—pancreatic cancer	3.62e-05	0.000106	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—AKT1—pancreatic cancer	3.6e-05	0.000105	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NOTCH1—pancreatic cancer	3.6e-05	0.000105	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NOTCH1—pancreatic cancer	3.59e-05	0.000105	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CG—pancreatic cancer	3.57e-05	0.000104	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—NRAS—pancreatic cancer	3.57e-05	0.000104	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NFKBIA—pancreatic cancer	3.56e-05	0.000104	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—AKT1—pancreatic cancer	3.55e-05	0.000104	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—APOE—pancreatic cancer	3.54e-05	0.000103	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—EGF—pancreatic cancer	3.53e-05	0.000103	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NOTCH1—pancreatic cancer	3.52e-05	0.000103	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CG—pancreatic cancer	3.52e-05	0.000103	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—NRAS—pancreatic cancer	3.52e-05	0.000103	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CG—pancreatic cancer	3.51e-05	0.000102	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—NRAS—pancreatic cancer	3.51e-05	0.000102	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CXCL8—pancreatic cancer	3.49e-05	0.000102	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—EGF—pancreatic cancer	3.48e-05	0.000101	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—KDR—pancreatic cancer	3.47e-05	0.000101	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—EGF—pancreatic cancer	3.47e-05	0.000101	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—HRAS—pancreatic cancer	3.46e-05	0.000101	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CG—pancreatic cancer	3.44e-05	0.0001	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—NRAS—pancreatic cancer	3.44e-05	0.0001	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—EGF—pancreatic cancer	3.4e-05	9.92e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—TYMS—pancreatic cancer	3.4e-05	9.9e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—SRC—pancreatic cancer	3.38e-05	9.84e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—AKT1—pancreatic cancer	3.37e-05	9.82e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PIK3CD—pancreatic cancer	3.36e-05	9.81e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CASP3—pancreatic cancer	3.34e-05	9.73e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—PIK3CA—pancreatic cancer	3.33e-05	9.7e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NFKBIA—pancreatic cancer	3.3e-05	9.63e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—VEGFA—pancreatic cancer	3.29e-05	9.59e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NOTCH1—pancreatic cancer	3.27e-05	9.54e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—STAT3—pancreatic cancer	3.26e-05	9.49e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—EGFR—pancreatic cancer	3.26e-05	9.49e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—NRAS—pancreatic cancer	3.25e-05	9.47e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CCND1—pancreatic cancer	3.25e-05	9.47e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—TP53—pancreatic cancer	3.22e-05	9.39e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CTNNB1—pancreatic cancer	3.22e-05	9.38e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—EGFR—pancreatic cancer	3.2e-05	9.34e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CG—pancreatic cancer	3.2e-05	9.33e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—NRAS—pancreatic cancer	3.2e-05	9.33e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—EGFR—pancreatic cancer	3.2e-05	9.32e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—EGF—pancreatic cancer	3.16e-05	9.22e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MMP9—pancreatic cancer	3.15e-05	9.19e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CD—pancreatic cancer	3.14e-05	9.16e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—EGFR—pancreatic cancer	3.14e-05	9.15e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PTEN—pancreatic cancer	3.13e-05	9.14e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.11e-05	9.07e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CD—pancreatic cancer	3.09e-05	9.01e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CD—pancreatic cancer	3.08e-05	8.99e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—HRAS—pancreatic cancer	3.08e-05	8.98e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—KRAS—pancreatic cancer	3.08e-05	8.97e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.06e-05	8.93e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—AKT1—pancreatic cancer	3.06e-05	8.92e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.06e-05	8.91e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CD—pancreatic cancer	3.03e-05	8.83e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—KRAS—pancreatic cancer	3.03e-05	8.82e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MYC—pancreatic cancer	3.03e-05	8.82e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—KRAS—pancreatic cancer	3.02e-05	8.81e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TGFB1—pancreatic cancer	3.02e-05	8.8e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	3e-05	8.74e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—KRAS—pancreatic cancer	2.96e-05	8.64e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—EGFR—pancreatic cancer	2.96e-05	8.63e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PIK3CB—pancreatic cancer	2.93e-05	8.55e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—EGFR—pancreatic cancer	2.91e-05	8.5e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—SRC—pancreatic cancer	2.91e-05	8.47e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PTGS2—pancreatic cancer	2.9e-05	8.47e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—VEGFA—pancreatic cancer	2.83e-05	8.25e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—PIK3CA—pancreatic cancer	2.83e-05	8.24e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CD—pancreatic cancer	2.81e-05	8.2e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—STAT3—pancreatic cancer	2.8e-05	8.17e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—NRAS—pancreatic cancer	2.8e-05	8.15e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—KRAS—pancreatic cancer	2.8e-05	8.15e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.79e-05	8.12e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—PIK3CA—pancreatic cancer	2.78e-05	8.11e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—PIK3CA—pancreatic cancer	2.77e-05	8.09e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—APOE—pancreatic cancer	2.76e-05	8.05e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—KRAS—pancreatic cancer	2.75e-05	8.03e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CB—pancreatic cancer	2.74e-05	7.98e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—PIK3CA—pancreatic cancer	2.72e-05	7.94e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—AKT1—pancreatic cancer	2.72e-05	7.93e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CB—pancreatic cancer	2.69e-05	7.86e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CB—pancreatic cancer	2.69e-05	7.84e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CB—pancreatic cancer	2.64e-05	7.69e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CXCL8—pancreatic cancer	2.63e-05	7.67e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—HRAS—pancreatic cancer	2.61e-05	7.62e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MYC—pancreatic cancer	2.6e-05	7.59e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TGFB1—pancreatic cancer	2.6e-05	7.58e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	2.59e-05	7.55e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CXCL8—pancreatic cancer	2.58e-05	7.53e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	2.57e-05	7.5e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—PIK3CA—pancreatic cancer	2.57e-05	7.49e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—HRAS—pancreatic cancer	2.57e-05	7.48e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—EGFR—pancreatic cancer	2.55e-05	7.43e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—AKT1—pancreatic cancer	2.54e-05	7.41e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CXCL8—pancreatic cancer	2.54e-05	7.39e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PTEN—pancreatic cancer	2.53e-05	7.39e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	2.53e-05	7.38e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—HRAS—pancreatic cancer	2.52e-05	7.34e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CASP3—pancreatic cancer	2.52e-05	7.34e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	2.5e-05	7.29e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—AKT1—pancreatic cancer	2.5e-05	7.28e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	2.49e-05	7.27e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TP53—pancreatic cancer	2.48e-05	7.25e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	2.48e-05	7.23e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CASP3—pancreatic cancer	2.47e-05	7.21e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CCND1—pancreatic cancer	2.45e-05	7.15e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	2.45e-05	7.15e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—AKT1—pancreatic cancer	2.45e-05	7.14e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CTNNB1—pancreatic cancer	2.43e-05	7.08e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CASP3—pancreatic cancer	2.43e-05	7.08e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	2.41e-05	7.03e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CCND1—pancreatic cancer	2.41e-05	7.02e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—KRAS—pancreatic cancer	2.41e-05	7.02e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PPARG—pancreatic cancer	2.41e-05	7.02e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	2.39e-05	6.97e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CTNNB1—pancreatic cancer	2.38e-05	6.95e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MMP9—pancreatic cancer	2.38e-05	6.94e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—HRAS—pancreatic cancer	2.38e-05	6.93e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PTEN—pancreatic cancer	2.37e-05	6.9e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	2.36e-05	6.89e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	2.36e-05	6.87e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	2.34e-05	6.83e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	2.34e-05	6.82e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	2.34e-05	6.82e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MMP9—pancreatic cancer	2.34e-05	6.81e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	2.33e-05	6.79e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PTEN—pancreatic cancer	2.32e-05	6.77e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	2.31e-05	6.73e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	2.29e-05	6.69e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	2.28e-05	6.65e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	2.28e-05	6.64e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	2.27e-05	6.62e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—AKT1—pancreatic cancer	2.27e-05	6.61e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	2.25e-05	6.57e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	2.22e-05	6.48e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PIK3CA—pancreatic cancer	2.21e-05	6.45e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	2.19e-05	6.4e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—SRC—pancreatic cancer	2.19e-05	6.4e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	2.19e-05	6.39e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	2.17e-05	6.34e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—SRC—pancreatic cancer	2.16e-05	6.3e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—SRC—pancreatic cancer	2.15e-05	6.28e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TP53—pancreatic cancer	2.14e-05	6.24e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	2.14e-05	6.23e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	2.13e-05	6.21e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	2.12e-05	6.18e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—STAT3—pancreatic cancer	2.12e-05	6.17e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	2.11e-05	6.16e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NRAS—pancreatic cancer	2.11e-05	6.16e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	2.1e-05	6.13e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—VEGFA—pancreatic cancer	2.1e-05	6.12e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—AKT1—pancreatic cancer	2.1e-05	6.12e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	2.08e-05	6.07e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—STAT3—pancreatic cancer	2.08e-05	6.06e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	2.08e-05	6.06e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NRAS—pancreatic cancer	2.07e-05	6.04e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	2.07e-05	6.03e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	2.06e-05	6e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—HRAS—pancreatic cancer	2.05e-05	5.96e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	2.04e-05	5.94e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	2.03e-05	5.93e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MYC—pancreatic cancer	1.97e-05	5.73e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	1.96e-05	5.73e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	1.96e-05	5.72e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MYC—pancreatic cancer	1.93e-05	5.64e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MYC—pancreatic cancer	1.93e-05	5.63e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	1.93e-05	5.63e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TGFB1—pancreatic cancer	1.93e-05	5.62e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—EGFR—pancreatic cancer	1.92e-05	5.61e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	1.91e-05	5.58e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	1.91e-05	5.57e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	1.89e-05	5.52e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	1.89e-05	5.52e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PTGS2—pancreatic cancer	1.89e-05	5.52e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	1.89e-05	5.52e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	1.89e-05	5.51e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	1.89e-05	5.51e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—EGFR—pancreatic cancer	1.89e-05	5.51e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	1.85e-05	5.4e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—KRAS—pancreatic cancer	1.82e-05	5.3e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—AKT1—pancreatic cancer	1.81e-05	5.27e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	1.79e-05	5.21e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	1.79e-05	5.21e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—KRAS—pancreatic cancer	1.78e-05	5.2e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	1.76e-05	5.13e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	1.76e-05	5.12e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	1.75e-05	5.1e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	1.72e-05	5.02e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	1.67e-05	4.87e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PTEN—pancreatic cancer	1.65e-05	4.81e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	1.64e-05	4.79e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CA—pancreatic cancer	1.64e-05	4.78e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	1.63e-05	4.74e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TP53—pancreatic cancer	1.61e-05	4.71e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	1.61e-05	4.69e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TP53—pancreatic cancer	1.59e-05	4.63e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TP53—pancreatic cancer	1.59e-05	4.62e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	1.56e-05	4.54e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—HRAS—pancreatic cancer	1.54e-05	4.5e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	1.52e-05	4.43e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—HRAS—pancreatic cancer	1.52e-05	4.42e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	1.49e-05	4.36e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	1.49e-05	4.34e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—AKT1—pancreatic cancer	1.46e-05	4.26e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	1.45e-05	4.22e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	1.38e-05	4.03e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—AKT1—pancreatic cancer	1.36e-05	3.98e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	1.34e-05	3.91e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—AKT1—pancreatic cancer	1.34e-05	3.9e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	1.31e-05	3.83e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	1.22e-05	3.56e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	1.16e-05	3.4e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—AKT1—pancreatic cancer	9.51e-06	2.77e-05	CbGpPWpGaD
